ALZHEIMER EUROPE

Their core work

Alzheimer Europe is a Luxembourg-based patient advocacy and knowledge organization that represents people with dementia and their carers across Europe. In H2020 projects, they serve as the bridge between clinical research and the patient perspective — contributing expertise in patient engagement, ethical frameworks, public involvement methodologies, and real-world evidence gathering. They coordinate communication and dissemination for major neurodegeneration research initiatives and provide structured input on how dementia research outcomes translate into care practice and policy. Their role ensures that large-scale clinical and digital health projects remain grounded in the lived experience of people affected by dementia.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Alzheimer Europe focused on traditional Alzheimer's disease research support — amyloid imaging (AMYPAD), real-world evidence platforms (ROADMAP), patient engagement models (MOPEAD), and health economics data. From 2019 onward, their work shifted decisively toward digital health tools, AI-driven screening (AI-Mind), personalized prediction models (LETHE), and broader neurodegeneration platforms (EPND, NEURONET). The recent period also shows expansion beyond pure Alzheimer's into cognitive decline linked to diabetes (RECOGNISED) and general dementia risk reduction using technology.

Alzheimer Europe is moving from traditional disease-focused advocacy toward technology-enabled early detection and prevention, making them an increasingly relevant partner for digital health and AI projects targeting cognitive decline.

How they like to work

Alzheimer Europe operates exclusively as a participant — they have never coordinated an H2020 project, instead contributing specialized patient-perspective expertise to large consortia. With 201 unique partners across 30 countries, they are a high-connectivity hub in the European dementia research network, consistently joining different consortia rather than repeatedly partnering with the same groups. This makes them an accessible, well-networked partner who brings established relationships across the entire European neurodegeneration landscape.

Exceptionally well-connected for an SME, with 201 unique consortium partners spanning 30 countries. Their network spans academic medical centers, pharmaceutical companies (via IMI projects), digital health SMEs, and national Alzheimer associations across Europe.

What sets them apart

Alzheimer Europe occupies a rare niche: they are the go-to European organization for embedding patient and carer perspectives into dementia research projects at scale. Unlike university research groups or clinical partners, they bring structured patient engagement methodology, ethical oversight capacity, and a continent-wide network of national Alzheimer associations. For any consortium targeting dementia, cognitive decline, or aging-related neurodegeneration, their involvement adds credibility with funders and ensures the patient voice is systematically integrated.

Highlights from their portfolio

• NEURONET
  Largest single grant (EUR 368K) — a coordination and support action that networked the entire IMI neurodegeneration project portfolio, placing AE at the hub of Europe's dementia research ecosystem.
• AI-Mind
  Represents their most advanced digital/AI engagement — using machine learning and deep learning for brain connectivity screening in people with mild cognitive impairment.
• EPND
  Second-largest grant (EUR 354K) and their most recent major project, building a pan-European platform for neurodegenerative disorders — signals their growing infrastructure role.